BioCentury
ARTICLE | Clinical News

Lung-MAP adds non-biomarker Opdivo arm

March 2, 2016 2:42 AM UTC

The Phase II/III Lung-MAP (S1400) lung cancer study now includes an arm that tests PD-1 inhibitor Opdivo nivolumab alone or in combination with Yervoy ipilimumab in patients who do not have a biomarker that matches any of the study's targeted therapies.

The "master protocol" trial is designed to evaluate several compounds simultaneously to treat squamous cell lung cancer. Patients are screened using the genomic platform from Foundation Medicine Inc. (NASDAQ:FMI) and assigned to treatment arms based on biomarker expression. Patients naive to checkpoint therapy who do not have a genomic match with any of the other therapies may elect to enroll in the Opdivo arm. ...